VRCA Q3 2025 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

VRCAVerrica Pharmaceuticals Inc.

$56M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+905.4% YoY

Gross Profit

$13M92.3% margin

Operating Income

$2M11.3% margin

Net Income

-$274,000-1.9% margin

EPS (Diluted)

$-0.03

QoQ Revenue Growth

+12.9%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$10M

Stock-Based Comp.

$718,000

Balance Sheet

Total Assets

$41M

Total Liabilities

$58M

Stockholders' Equity

-$17M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	-$2M	+905.4%
Gross Profit	$13M	-$2M	+697.2%
Operating Income	$2M	-$21M	+107.9%
Net Income	-$274,000	-$23M	+98.8%

Revenue Segments

License And Collaboration Revenue

$11M75%

Product

$4M25%